retatrutide clinical trials data Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide for Weight Loss: TRIUMPH-1

Another study compared patients with obesity and hypothalamic damage, patients without obesity and hypothalamic damage, controls with obesity and normal-weight controls (Steele et al., 2015)

After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer decided to discontinue development of the molecule

CYP2D6 Poor Metabolizers Approximately 5 to 10% of Caucasians and 1 to 2% of East Asian populations are CYP2D6 poor metabolizers, meaning they clear amphetamine more slowly and may experience higher plasma levels at standard doses [2]

Not for glycemic control or obesity or even cardiovascular disease, but for kidney disease. Dr